A Study to Improve Skeletal Muscle in Veterans With HIV
A Randomized Trial to Optimize Skeletal Muscle While Reducing Adiposity in Veterans With HIV
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Heidi J Silver, PhD
- Phone Number: (615) 875-9355
- Email: heidi.j.silver@vumc.org
Study Contact Backup
- Name: John R Koethe, MD
- Phone Number: (615) 873-6188
- Email: john.koethe@va.gov
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212-2637
- Recruiting
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
-
Principal Investigator:
- Heidi J Silver, PhD
-
Contact:
- Geraldine M Freddie
- Phone Number: (615) 873-8694
- Email: Geraldine.Freddie@va.gov
-
Principal Investigator:
- John R Koethe, MD
-
Contact:
- Patrick M Lynch
- Phone Number: (615) 873-6927
- Email: Patrick.Lynch2@va.gov
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Veteran
- HIV+
- antiretroviral therapy = integrase strand transfer inhibitor for at least 3 months
- HIV-1 RNA <50 copies/ml
- age = 20 yrs
- BMI 28-50 kg/m2
Exclusion Criteria:
- unstable body weight (gain or loss > 5% over past 3 months)
- diagnosed mitochondrial disorder
- diagnosed type 1 or type 2 diabetes
- use of metformin or other anti-diabetic agents for pre-diabetes
- hemoglobin A1c of >6.5% at screening visit
- inflammatory conditions or chronic corticosteroid use
- stage 3 or greater kidney disease
- dietary or herbal supplements known to affect body weight, muscle mass, or immune function
- MRI incompatibility
- inability to perform physical function tests due to anatomical limitations
- contradictions to CPET such as exercise-induced ischemia or supplemental oxygen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Control Diet
Diet high in unsaturated fat
|
Control Diet high in unsaturated fat
|
|
Experimental: Diet + w-3 fatty acids
Diet high in unsaturated fat plus omega-3 fatty acid supplement
|
Control Diet high in unsaturated fat
omega-3 fatty acid supplement
|
|
Experimental: Diet + L-Carnitine
Diet high in unsaturated fat plus L-carnitine supplement
|
Control Diet high in unsaturated fat
L-carnitine supplement
|
|
Experimental: Diet + w-3 fatty acids + L-carnitine
Diet high in unsaturated fat plus omega-3 fatty acid supplement plus L-carnitine supplement
|
Control Diet high in unsaturated fat
omega-3 fatty acid supplement
L-carnitine supplement
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Myosteatosis
Time Frame: Week 24 and 44
|
CT quantified abdominal skeletal muscle density
|
Week 24 and 44
|
|
MixedMeal GTT
Time Frame: Week 24 and 44
|
IV Glucose tolerance testing after consumption of BOOST as a meal substitute
|
Week 24 and 44
|
|
Physical Function
Time Frame: Week 24 and 44
|
Physical Function Testing using Hand Grip Strength Dynamometer
|
Week 24 and 44
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Heidi J Silver, PhD, Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
- Principal Investigator: John R Koethe, MD, Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- INFA-009-24F
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.